null

null

null

null

null

null

null

null

null

null

null

null

null

0.00x Total Debt / Equity (Conservative)

Low sensitivity; Cumberland carries minimal long-term debt (~$5M credit facility), so a 200bps rate rise adds <$100K annual interest expense

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Indian API manufacturers (generic drug intermediates) and Chinese raw chemical precursors represent top-two geopolitical chokepoints

Minimal exposure; Cumberland derives ~95% of revenue domestically, with negligible sovereign currency devaluation risk in international markets

Predominantly US-focused (~95% domestic revenue); negligible FX devaluation risk from international markets, no material top-three foreign revenue geographies

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High lock-in risk; single-source API suppliers for niche hospital products (e.g., Acetadote) likely exceed 30% input cost and lack easy substitutes

Minimal cloud disruption risk; Cumberland is a specialty pharma company, not SaaS-dependent — core ops use ERP/CRM on-premise or low-criticality cloud tools

Specialty pharmaceutical manufacturer and marketer; secondary model is licensing/royalty revenue from out-licensed compounds

Low API coupling risk; Cumberland does not sell APIs or software integrations — distribution relies on standard pharmaceutical wholesale EDI channels

Fails Howey Test; revenue from pharmaceutical product sales and royalties does not constitute an investment contract — near-zero securities law reclassification risk

Very High

Low GDPR exposure given minimal EU operations; moderate CCPA risk from patient support program data collection, but not a core revenue-model dependency

Low-moderate; niche hospital drug portfolio with small market share, though branded pricing on off-patent drugs (e.g., Kristalose) could attract scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~85% product sales); some recurring royalty/milestone revenue (~15%) from licensing agreements

Direct pharmaceutical product sales through wholesale distributors (McKesson, Cardinal, AmerisourceBergen) plus royalty streams from out-licensed assets

WAC-based branded drug pricing with GPO/PBM contract discounts; pricing power constrained by generic competition and hospital formulary committee pressure

Weak-to-moderate; niche hospital products have some formulary stickiness, but generic threats and payer pushback limit sustained price increases above CPI

Gross margins approximately 60–70%; specialty pharma norm, but Cumberland's small scale limits manufacturing leverage versus large-cap peers

No meaningful free-rider problem; pharmaceutical products are purchased and consumed — no digital/open-source equivalent creating leakage

Sublinear growth possible; small specialty sales force (~50 reps) already covers target hospitals — revenue can grow via new product additions without proportional headcount increase

Low marginal cost for existing products via distribution leverage; new product launches require incremental sales force and promotional spend, making growth semi-linear

Not applicable; Cumberland operates no franchise network — direct sales and distribution model only

At 10x scale, hospital formulary access and GPO contract wins become bottlenecks; CAC likely rises as addressable hospital targets are exhausted in niche indications

No network effects present; pharmaceutical product utility is independent of user base size — adoption driven by clinical evidence and formulary access

-8.4% Return on Assets (Negative equity)

Tier 1 recession-resistant; hospital-administered drugs (IV acetaminophen, Acetadote) address acute medical needs with inelastic demand regardless of economic cycle

Hospital systems and acute-care institutions (~70% of revenue); top wholesalers McKesson/Cardinal/AmerisourceBergen create concentration risk at distribution layer

Retail pharmacy and outpatient patients for GI products (Kristalose, Vaprisol); secondary segment more susceptible to generic substitution and payer formulary exclusion

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.2% CapEx / Revenue (Low-CapEx Asset-Light)

0001087294

CPIX